Over the past few decades, substantial evidence has convincingly revealed the existence of
cancer stem cells (CSCs) as a minor subpopulation in cancers, contributing to an aberrantly …

The complexity of glioblastoma multiforme, the most common and lethal variant of gliomas,
is reflected by cellular and molecular heterogeneity at both the inter-and intra-tumoural …

Glioblastoma (GBM) is the most aggressive primary brain tumor in adults, with a poor
prognosis, despite surgical resection combined with radio-and chemotherapy. The major …

Intra-tumoral heterogeneity is a hallmark of glioblastoma that challenges treatment efficacy.
However, the mechanisms that set up tumor heterogeneity and tumor cell migration remain …

Glioblastoma is the most malignant tumor occurring in the human central nervous system
with overall median survival time< 14.6 months. Current treatments such as chemotherapy …

The acquisition of temozolomide resistance is a major clinical challenge for glioblastoma
treatment. Chemoresistance in glioblastoma is largely attributed to repair of temozolomide …

Dysregulation of transcription factors is one of the common problems in the pathogenesis of
human cancer. Among them, SOX9 is one of the critical transcription factors involved in …

The prevalence of head and neck squamous cell carcinoma (HNSCC) has continued to rise
for decades. However, drug resistance to chemotherapeutics and relapse, mediated by …

The chemokine CCL5/RANTES is a versatile inflammatory mediator, which interacts with the
receptor CCR5, promoting cancer cell interactions within the tumor microenvironment …

Simple Summary Glioblastoma stem-like cells (GSCs) drive the progression and therapeutic
resistance of glioblastoma. GSC plasticity allows them to adapt to different …